VolitionRx Limited (VNRX)
NYSEAMERICAN: VNRX · Real-Time Price · USD
0.4867
+0.0067 (1.40%)
At close: Apr 23, 2025, 4:00 PM
0.4600
-0.0267 (-5.49%)
After-hours: Apr 23, 2025, 4:42 PM EDT
Company Description
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and diseases associated with NETosis such as sepsis in the United States and internationally.
It offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis such as sepsis; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
VolitionRx Limited is based in Henderson, Nevada.
VolitionRx Limited
| Country | United States |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 85 |
| CEO | Cameron Reynolds |
Contact Details
Address: 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 United States | |
| Phone | 646 650 1351 |
| Website | volition.com |
Stock Details
| Ticker Symbol | VNRX |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000093314 |
| CUSIP Number | 928661107 |
| ISIN Number | US9286611077 |
| Employer ID | 91-1949078 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Salvatore Thomas Butera DVM | Chief Executive Officer of Volition Veterinary Diagnostics Development LLC |
| Cameron Reynolds MBA | Founder, Chief Executive Officer, President and Director |
| Dr. Gaetan Michel Ph.D. | Chief Operating Officer |
| Terig Hughes | Chief Financial Officer and Treasurer |
| Dr. Jacob Vincent Micallef MBA, Ph.D. | Chief Scientific Officer |
| Nicholas Plummer | Group General Counsel |
| Louise Batchelor Day | Group Chief Marketing and Communications Officer |
| Gael Forterre M.B.A. | Chief Commercial Officer |
| Sharon Ballesteros | U.S. Head of Quality and Development Process |
| Dr. Andrew Retter MBBS | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2025 | 8-K | Current Report |
| Apr 22, 2025 | 424B5 | Filing |
| Apr 18, 2025 | EFFECT | Notice of Effectiveness |
| Apr 16, 2025 | RW | Filing |
| Apr 15, 2025 | EFFECT | Notice of Effectiveness |
| Apr 11, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Apr 7, 2025 | SCHEDULE 13G/A | Filing |
| Apr 4, 2025 | 8-K | Current Report |
| Apr 4, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 4, 2025 | PRE 14A | Other preliminary proxy statements |